PFIZER, SEARLE EXECS NAMED TO HEALTH CARE POLICY AND RESEARCH ADVISORY GROUP
PFIZER, SEARLE EXECS NAMED TO HEALTH CARE POLICY AND RESEARCH ADVISORY GROUP, HHS announced Sept. 20. Edward Bessey, Pfizer Hospital Products Group president, was designated a representative of "business" concerns. Searle Senior VP Joseph Curti will serve as a medical practice representative. Curti, nominated by the Pharmaceutical Manufacturers Association, is also on the board of trustees at Morehouse medical school, where HHS Secretary Sullivan was founder and president. The newly established council will be an advisory group to the Public Health Service Agency for Health Care Policy and Research (AHCPR). The agency supplanted the National Center for Health Services Research, with expanded duties, as directed by the 1989 budget reconciliation law. In addition to developing Medicare coverage recommendations and funding a variety of health research services, the agency will support comparative research on the outcomes of health procedures and development of guidelines for medical practice. The advisory council will focus on the latter tasks. Bessey had been a member of NCHSR's advisory council. The 17-member panel will meet at least three times a year. Other members include American Society of Internal Medicine Executive VP Joe Boyle, MD, and Walter McNerny, Northwestern University health policy professor and the panel's "public policy" representative.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth